F8 and hemophilia A: In 2017, the FVIII gene trial of intravenous AAV5 (valxaparvovec) was reported in patients with hemophilia A. Long-term data after 3 years of follow-up showed a significant reduction in FVIII expression compared to the FVIII level at 1 year (Pasi et al., 2020).